Lymphir is supplied as a 300mcg lyophilized cake in a single-dose vial for reconstitution and further dilution.

“LYMPHIR is an important new treatment option for the CTCL community, and its launch marks the beginning of a new chapter for Citius Oncology,” Leonard Mazur, chairman and CEO of Citius Oncology and ...

The U.S. commercial launch of LYMPHIR (denileukin diftitox-cxdl), a novel cancer immunotherapy for adults with relapsed or ...

JAK2 gene fusion appears across multiple CTCL types, shaping diagnosis and treatment opportunities. Learn more about its ...

Citius Oncology launches US FDA approved Lymphir, a novel cancer immunotherapy for cutaneous T-cell lymphoma: Cranford, New Jersey Wednesday, December 3, 2025, 16:00 Hrs [IST] Cit ...

An announcement from Citius Oncology ( ($CTOR) ) is now available. On December 1, 2025, Citius Oncology announced the commercial launch of ...

The global T-Cell lymphoma therapeutics market size was valued at US$ 2.3 Bn in 2024 and is projected to reach US$ 5.7 Bn by ...

Citius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), the oncology-focused subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (Nasdaq: CTXR), today announced the commercial launch of ...

Mature nodal T-cell lymphoma is a type of rare and aggressive blood cancer. Limited data make it difficult to identify ...